**Core Concept**
Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection that affects immunocompromised patients, particularly those with HIV/AIDS. The treatment of choice for PCP is a medication that targets the fungal pathogen, preventing its growth and replication.

**Why the Correct Answer is Right**
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line treatment for PCP due to its broad-spectrum antimicrobial activity. TMP-SMX inhibits dihydrofolate reductase, an enzyme essential for the synthesis of tetrahydrofolate, a precursor to thymidine and purines. This disrupts DNA synthesis and cell division in the fungal pathogen, ultimately leading to its eradication. The combination of TMP and SMX also enhances the efficacy of the treatment and reduces the risk of resistance.

**Why Each Wrong Option is Incorrect**
**Option A:** Pentamidine is an alternative treatment for PCP, but it is not the first-line choice due to its toxicity and potential side effects.
**Option B:** Clindamycin is an antibiotic with a narrow spectrum of activity and is not effective against Pneumocystis jirovecii.
**Option C:** Fluconazole is an antifungal medication, but it is not the preferred treatment for PCP due to its lower efficacy and potential for resistance.

**Clinical Pearl / High-Yield Fact**
PCP is a leading cause of morbidity and mortality in HIV-infected individuals, particularly those with CD4 counts below 200 cells/μL. Early recognition and treatment of PCP are critical to prevent severe respiratory complications and improve patient outcomes.

**Correct Answer: C. Trimethoprim-sulfamethoxazole**